JP2005515771A - 髄膜炎性疾患の予防および治療のための新規免疫原性組成物 - Google Patents

髄膜炎性疾患の予防および治療のための新規免疫原性組成物 Download PDF

Info

Publication number
JP2005515771A
JP2005515771A JP2003563462A JP2003563462A JP2005515771A JP 2005515771 A JP2005515771 A JP 2005515771A JP 2003563462 A JP2003563462 A JP 2003563462A JP 2003563462 A JP2003563462 A JP 2003563462A JP 2005515771 A JP2005515771 A JP 2005515771A
Authority
JP
Japan
Prior art keywords
composition
protein
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003563462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005515771A5 (cg-RX-API-DMAC10.html
Inventor
ズロトニック，ゲーリー・ダブリュー
フレッチヤー，リー・ディー
ファーリー，ジョン
バーンフィールド，リーセル・エイ
ザガースキー，ロバート・ジェイ
メットカーフ，ベンジャミン・ジェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Wyeth Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27668840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2005515771(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Holdings LLC filed Critical Wyeth Holdings LLC
Publication of JP2005515771A publication Critical patent/JP2005515771A/ja
Publication of JP2005515771A5 publication Critical patent/JP2005515771A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2414—Alpha-amylase (3.2.1.1.)
    • C12N9/2417—Alpha-amylase (3.2.1.1.) from microbiological source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
JP2003563462A 2001-10-11 2002-10-11 髄膜炎性疾患の予防および治療のための新規免疫原性組成物 Pending JP2005515771A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32810101P 2001-10-11 2001-10-11
US40693402P 2002-08-30 2002-08-30
PCT/US2002/032369 WO2003063766A2 (en) 2001-10-11 2002-10-11 Novel immunogenic compositions for the prevention and treatment of meningococcal disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010007996A Division JP5404441B2 (ja) 2001-10-11 2010-01-18 髄膜炎性疾患の予防および治療のための新規免疫原性組成物

Publications (2)

Publication Number Publication Date
JP2005515771A true JP2005515771A (ja) 2005-06-02
JP2005515771A5 JP2005515771A5 (cg-RX-API-DMAC10.html) 2006-01-05

Family

ID=27668840

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2003563462A Pending JP2005515771A (ja) 2001-10-11 2002-10-11 髄膜炎性疾患の予防および治療のための新規免疫原性組成物
JP2010007996A Expired - Lifetime JP5404441B2 (ja) 2001-10-11 2010-01-18 髄膜炎性疾患の予防および治療のための新規免疫原性組成物
JP2013158937A Expired - Lifetime JP5923070B2 (ja) 2001-10-11 2013-07-31 髄膜炎性疾患の予防および治療のための新規免疫原性組成物
JP2015100931A Expired - Lifetime JP5976880B2 (ja) 2001-10-11 2015-05-18 髄膜炎性疾患の予防および治療のための新規免疫原性組成物
JP2016040311A Expired - Lifetime JP5997400B2 (ja) 2001-10-11 2016-03-02 髄膜炎性疾患の予防および治療のための新規免疫原性組成物
JP2016143674A Withdrawn JP2017025061A (ja) 2001-10-11 2016-07-21 髄膜炎性疾患の予防および治療のための新規免疫原性組成物

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2010007996A Expired - Lifetime JP5404441B2 (ja) 2001-10-11 2010-01-18 髄膜炎性疾患の予防および治療のための新規免疫原性組成物
JP2013158937A Expired - Lifetime JP5923070B2 (ja) 2001-10-11 2013-07-31 髄膜炎性疾患の予防および治療のための新規免疫原性組成物
JP2015100931A Expired - Lifetime JP5976880B2 (ja) 2001-10-11 2015-05-18 髄膜炎性疾患の予防および治療のための新規免疫原性組成物
JP2016040311A Expired - Lifetime JP5997400B2 (ja) 2001-10-11 2016-03-02 髄膜炎性疾患の予防および治療のための新規免疫原性組成物
JP2016143674A Withdrawn JP2017025061A (ja) 2001-10-11 2016-07-21 髄膜炎性疾患の予防および治療のための新規免疫原性組成物

Country Status (18)

Country Link
US (13) US8101194B2 (cg-RX-API-DMAC10.html)
EP (14) EP2348034B1 (cg-RX-API-DMAC10.html)
JP (6) JP2005515771A (cg-RX-API-DMAC10.html)
KR (4) KR101215664B1 (cg-RX-API-DMAC10.html)
CN (4) CN105617372A (cg-RX-API-DMAC10.html)
AU (3) AU2009213040C1 (cg-RX-API-DMAC10.html)
BE (3) BE2017C057I2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0212999B8 (cg-RX-API-DMAC10.html)
CA (5) CA2849427C (cg-RX-API-DMAC10.html)
DK (10) DK2371836T3 (cg-RX-API-DMAC10.html)
ES (14) ES2603531T3 (cg-RX-API-DMAC10.html)
FR (4) FR15C0056I2 (cg-RX-API-DMAC10.html)
IL (5) IL161052A0 (cg-RX-API-DMAC10.html)
LU (4) LU92786I2 (cg-RX-API-DMAC10.html)
MX (3) MX339524B (cg-RX-API-DMAC10.html)
NL (4) NL300755I2 (cg-RX-API-DMAC10.html)
PT (10) PT2348035E (cg-RX-API-DMAC10.html)
WO (1) WO2003063766A2 (cg-RX-API-DMAC10.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525330A (ja) * 2003-04-16 2006-11-09 ワイエス・ホールディングス・コーポレーション 髄膜炎菌性疾患の予防および処置のための新規免疫原性組成物
JP2010162038A (ja) * 2002-11-22 2010-07-29 Chiron Srl 髄膜炎菌タンパク質ｎｍｂ１８７０の複数の改変体
JP2013537884A (ja) * 2010-09-10 2013-10-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 髄膜炎菌に対するワクチン
JP2013540705A (ja) * 2010-08-23 2013-11-07 ワイス・エルエルシー ナイセリア・メニンギティディス（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）ｒＬＰ２０８６抗原の安定な製剤
JP2013540432A (ja) * 2010-09-10 2013-11-07 ワイス・エルエルシー 髄膜炎菌ｏｒｆ２０８６抗原の非脂質化変異体
JP2016222701A (ja) * 2006-04-26 2016-12-28 ワイス・エルエルシー 免疫原性組成物を安定化させ、沈殿を阻害する新規製剤

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261350A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
NZ545647A (en) 1999-05-19 2008-02-29 Chiron Srl Combination neisserial compositions
PT2275552E (pt) 1999-10-29 2015-12-07 Glaxosmithkline Biolog Sa Péptidos antigénicos de neisseria
BR0107679A (pt) 2000-01-17 2004-07-06 Chiron Spa Vacina de vesìcula de membrana externa (omv) compreendendo proteìnas de membrana externa do grupo sérico b de neisseria meningitidis
AU2001239488B2 (en) 2000-02-28 2006-01-19 Glaxosmithkline Biologicals S.A. Heterologous expression of neisserial proteins
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE60335477D1 (de) 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
EP2191844B1 (en) 2003-01-30 2014-03-05 Novartis AG Injectable vaccines against multiple meningococcal serogroups
CA2885040C (en) 2003-10-02 2018-10-30 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
EP2425853A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
KR101408113B1 (ko) 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2013201318B2 (en) * 2005-11-25 2015-11-19 Glaxosmithkline Biologicals Sa Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CA2657135C (en) 2006-07-27 2016-03-15 Wyeth High-cell density fed-batch fermentation process for producing recombinant protein
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
BRPI0907843A2 (pt) 2008-02-21 2015-08-04 Novartis Ag Polipeptídeos de fhbp menigocócicos
US20100189737A1 (en) 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
NZ595291A (en) 2009-03-24 2013-08-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
RU2557315C2 (ru) 2009-03-24 2015-07-20 Новартис Аг Адъювантный менингококковый белок, связывающий фактор н
WO2011008400A2 (en) 2009-06-16 2011-01-20 Novartis Ag High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
EP2470205A1 (en) 2009-08-27 2012-07-04 Novartis AG Adjuvant comprising aluminium, oligonucleotide and polycation
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
EP4036104B1 (en) 2010-03-30 2024-02-21 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
DK3170508T3 (da) 2010-06-04 2020-01-02 Wyeth Llc Vaccineformuleringer
US10478483B2 (en) * 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
WO2013098589A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
JP5957541B2 (ja) 2012-02-02 2016-07-27 ノバルティス アーゲー 髄膜炎菌における増加したタンパク質発現のためのプロモータ
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
CN104159603A (zh) 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
JP5925342B2 (ja) * 2012-03-09 2016-05-25 ファイザー・インク 髄膜炎菌（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法
BR112014031386A2 (pt) 2012-06-14 2017-08-01 Pasteur Institut vacinas para meningococos do sorogrupo x
CA2875391A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
EP3027206A4 (en) 2013-08-02 2017-03-08 Children's Hospital & Research Center Oakland Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof
CA2923129C (en) * 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3110442B1 (en) 2014-02-28 2020-10-14 GlaxoSmithKline Biologicals SA Modified meningococcal fhbp polypeptides
JP6796057B2 (ja) 2014-07-23 2020-12-02 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド Ｈ因子結合タンパク質変異体及びその使用方法
WO2016081314A1 (en) 2014-11-17 2016-05-26 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to a complement inhibitor
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EP3263695A1 (en) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
CN106434720A (zh) * 2016-08-03 2017-02-22 中国医学科学院医学生物学研究所 提高脑膜炎奈瑟菌fHBP蛋白表达的方法
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
HRP20240433T1 (hr) 2016-09-02 2024-07-05 Sanofi Pasteur, Inc. Cjepivo protiv neisseria meningitidis
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
IL303108B2 (en) 2017-01-31 2024-07-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor
WO2019065555A1 (ja) 2017-09-28 2019-04-04 富士フイルム株式会社 撮像装置、情報取得方法及び情報取得プログラム
WO2019065554A1 (ja) * 2017-09-28 2019-04-04 富士フイルム株式会社 撮像装置、情報取得方法及び情報取得プログラム
TWI687696B (zh) * 2019-06-26 2020-03-11 國立中興大學 回饋型隱藏式馬可夫模型辨識器的建立方法與基於此辨識器的辨識系統的建立方法
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN114681601B (zh) * 2020-12-31 2025-08-19 基础治疗有限公司 脑膜炎奈瑟氏球菌疫苗及其应用
CA3211240A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
WO2023138914A1 (en) 2022-01-24 2023-07-27 Koninklijke Philips N.V. Pulse wave velocity determination using co-registration between intravascular data and extraluminal image, and associated systems, devices, and methods
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
WO2025199107A1 (en) 2024-03-19 2025-09-25 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
CN120227449A (zh) * 2025-05-21 2025-07-01 苏州聚微生物科技有限公司 B群脑膜炎球菌疫苗组合物及其制备方法与应用
CN120241991B (zh) * 2025-06-05 2025-12-23 北京绿竹生物技术股份有限公司 一种新型的b群流脑外膜蛋白双功能载体

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07508972A (ja) * 1989-03-09 1995-10-05 アメリカン・サイアナミド・カンパニー 分類できないヘモフイルス・インフルエンザエに対するワクチン
WO1996040718A1 (en) * 1995-06-07 1996-12-19 Connaught Laboratories, Inc. Expression of lipoproteins
WO1999040200A1 (en) * 1998-02-03 1999-08-12 Center For Disease Control And Prevention RECOMBINANT LIPIDATED PsaA PROTEIN, METHODS OF PREPARATION AND USE
WO1999057280A2 (en) * 1998-05-01 1999-11-11 Chiron Corporation Neisseria meningitidis antigens and compositions
WO2001037863A2 (en) * 1999-11-29 2001-05-31 Chiron Spa Compositions comprising neisseria meningitidis antigens from serogroups b and c as well as a further antigen
WO2001064920A2 (en) * 2000-02-28 2001-09-07 Chiron Spa Hybrid expression of neisserial proteins

Family Cites Families (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT280356B (de) 1968-03-06 1970-04-10 Telefonbau & Normalzeit Gmbh Schaltungsanordnung zur Steuerung des zur Zwischenspeicherung des Zeitwertes eines Signales verwendeten Kondensators eines Demodulators einer Zeitmultiplexanlage
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
CH660375A5 (it) 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4668829A (en) * 1984-07-18 1987-05-26 University Patents, Inc. Ferroelectric smectic liquid crystals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
WO1987001130A1 (en) 1985-08-15 1987-02-26 Stauffer Chemical Company Tryptophan producing microorganism
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
RU2023448C1 (ru) 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
JPH01144977A (ja) 1987-11-30 1989-06-07 Agency Of Ind Science & Technol 新規組換えプラスミドｐＴＰＧＩＦ２
CA1315719C (en) 1988-02-05 1993-04-06 Arthur Bank Retroviral packaging cell lines and processes of using same
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JP3082204B2 (ja) 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
IE912559A1 (en) 1990-07-19 1992-01-29 Merck & Co Inc The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
JPH0453645U (cg-RX-API-DMAC10.html) * 1990-09-12 1992-05-07
WO1992005263A1 (en) 1990-09-25 1992-04-02 Cantab Pharmaceuticals Research Limited Viral defective vaccine produced by transcomplementing cell line
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
WO1993007897A1 (en) 1991-10-21 1993-04-29 Medimmune, Inc. Bacterial expression vectors containing dna encoding secretion signals of lipoproteins
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
WO1993015115A1 (en) 1992-01-24 1993-08-05 Cornell Research Foundation, Inc. E. coli dna polymerase iii holoenzyme and subunits
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
DE69434079T2 (de) 1993-03-05 2005-02-24 Wyeth Holdings Corp. Plasmid zur Herstellung von CRM-Protein und Diphtherie-Toxin
AU696336B2 (en) 1993-03-19 1998-09-10 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. HSV) as vaccine
ATE190502T1 (de) * 1993-05-13 2000-04-15 American Cyanamid Co Herstellung und verwendungen von los-verminderten aussenmembran-proteinen von gram-negativen kokken
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
NZ269156A (en) 1993-07-13 1996-03-26 Rhone Poulenc Rorer Sa Defective recombinant adenovirus vector incapable of replicating autonomously in a target cell and its use in gene therapy
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5906928A (en) 1993-07-30 1999-05-25 University Of Medicine And Dentistry Of New Jersey Efficient gene transfer into primary murine lymphocytes obviating the need for drug selection
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US5550213A (en) 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FI98045C (fi) 1994-02-21 1997-04-10 Arto Remes Laite inkontinenssihoitoa varten
FR2716459B1 (fr) 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
AU2194895A (en) 1994-03-25 1995-10-17 Uab Research Foundation, The Composition and methods for creating syngeneic recombinant virus-producing cells
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
EP0753069A1 (en) 1994-04-15 1997-01-15 Targeted Genetics Corporation Gene delivery fusion proteins
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
DK0710118T3 (da) * 1994-04-20 1999-08-09 Us Army Vaccine mod infektioner med gram-negative bakterier
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
AU6043396A (en) 1995-06-05 1996-12-24 University Of Alabama At Birmingham Research Foundation, The Composition and methods for creating syngeneic recombinant v irus-producing cells
FR2741358B1 (fr) 1995-11-17 1998-01-02 Centre Nat Rech Scient Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
EP0922059B1 (en) 1996-08-27 2003-10-22 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
DK0939647T4 (da) 1996-08-27 2006-10-23 Novartis Vaccines & Diagnostic Neisseria Meningitidis-serogruppe B-glycokonjugat og fremgangsmåde til anvendelse deraf
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
AU5426098A (en) 1996-10-24 1998-05-15 Emory University Invasion associated genes from (neisseria meningitidis) serogroup
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
DE19723095C2 (de) 1997-06-02 2001-08-23 Siemens Ag Bildrekonstruktionsverfahren für einen Computertomographen
KR20010014298A (ko) 1997-06-30 2001-02-26 아방티 파르마 소시에테 아노님 핵산 벡터의 생체 내 조직으로의 적정화된 전기전달 장치
DE69826124T3 (de) 1997-06-30 2007-10-11 Institut Gustave Roussy Verabreichung der nukleinsäure in den quergestreiften muskel
CA2294802A1 (fr) 1997-06-30 1999-01-14 Michel Bureau Amelioration du transfert d'acide nucleique dans les cellules d'organismes eucaryotes pluricellulaires et combinaison permettant la mise en oeuvre du procede
CN1272062A (zh) * 1997-07-17 2000-11-01 北美疫苗公司 含有b组脑膜炎球菌膜孔蛋白和流感嗜血菌多糖的免疫偶联物
JPH1144977A (ja) 1997-07-25 1999-02-16 Copyer Co Ltd 画像形成装置
ATE505478T1 (de) 1997-08-27 2011-04-15 Novartis Vaccines & Diagnostic Molekular-mimetika von meningokokkalen b epitopen
US6207775B1 (en) * 1997-08-29 2001-03-27 The Dow Chemical Company Homogeneous filled polymer composite
WO1999024578A2 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CN1224708C (zh) 1998-01-14 2005-10-26 启龙股份公司 脑膜炎奈瑟氏球菌抗原
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808734D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
JP5074644B2 (ja) 1998-05-29 2012-11-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 組合わせの髄膜炎菌ｂ／ｃワクチン
JP4673974B2 (ja) 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン
ATE274353T1 (de) 1998-09-30 2004-09-15 Us Army Verwendung von aufgereinigtem invaplex als impfstoff für gram-negativebakterien
EP1559795A3 (en) 1998-10-09 2005-11-09 Chiron Corporation Neisseria genomic sequences and methods of their use
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6281337B1 (en) 1998-11-12 2001-08-28 Schering Corporation Methods for conversion of protein isoforms
JP2004537954A (ja) 1999-01-15 2004-12-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ナイセリア・メニンギティディス・ポリペプチドｂａｓｂ０５２
CA2360658A1 (en) 1999-01-22 2000-07-27 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
GB9902084D0 (en) * 1999-01-29 1999-03-24 Smithkline Beecham Biolog Novel compounds
DE60040727D1 (de) 1999-02-05 2008-12-18 Merck & Co Inc Menschliche papillomavirus impfstoff-formulierungen
DE60015084T2 (de) 1999-02-26 2006-02-16 Chiron S.R.L. Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
DE60042114D1 (de) 1999-04-30 2009-06-10 Craig J Venter Inst Inc Genomische sequenzen von neisseria und verfahren zu ihrer verwendung
NZ530640A (en) 1999-04-30 2006-06-30 Chiron S Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
NZ545647A (en) * 1999-05-19 2008-02-29 Chiron Srl Combination neisserial compositions
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
PT2275552E (pt) 1999-10-29 2015-12-07 Glaxosmithkline Biolog Sa Péptidos antigénicos de neisseria
EP1234039A2 (en) 1999-11-29 2002-08-28 Chiron Spa 85kDa NEISSERIAL ANTIGEN
PT1233784E (pt) 1999-12-02 2008-11-03 Novartis Vaccines & Diagnostic Composições e métodos para a estabilização de moléculas biológicas após a liofilização
BR0107679A (pt) 2000-01-17 2004-07-06 Chiron Spa Vacina de vesìcula de membrana externa (omv) compreendendo proteìnas de membrana externa do grupo sérico b de neisseria meningitidis
AU2001281812B2 (en) 2000-06-08 2005-04-07 Valneva Austria Gmbh Immunostimulatory oligodeoxynucleotides
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AP1897A (en) 2001-01-23 2008-10-10 Aventis Pasteur Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine.
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
WO2002079246A2 (en) 2001-03-30 2002-10-10 Geneprot, Inc. Human arginine-rich protein-related compositions
US6942802B2 (en) 2001-04-13 2005-09-13 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
CN1306956C (zh) 2001-04-17 2007-03-28 希龙公司 诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物
EP1404279A4 (en) 2001-06-07 2007-08-08 Wyeth Corp MUTANT FORMS OF CHOLERA HOLOTOXIN AS ADJUVANT
CN1297316C (zh) 2001-06-07 2007-01-31 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CA2452720C (en) 2001-07-26 2012-04-17 Chiron S.R.L. Vaccines comprising aluminium adjuvants and histidine
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
CA2460546A1 (en) 2001-09-14 2003-03-27 Invitrogen Corporation Dna polymerases and mutants thereof
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0129007D0 (en) 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
WO2003080678A1 (en) 2002-03-26 2003-10-02 Chiron Srl Modified saccharides having improved stability in water
DE60328481D1 (de) 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
BR0310042A (pt) 2002-05-14 2005-04-05 Chiron Srl Vacinas de combinação mucosal para meningite bacteriana
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
DE60335477D1 (de) 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
EP2279746B1 (en) 2002-11-15 2013-10-02 Novartis Vaccines and Diagnostics S.r.l. Surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US20070148729A1 (en) 2003-01-15 2007-06-28 Farley John E Methods for increasing neisseria protein expression and compositions thereof
EP2191844B1 (en) 2003-01-30 2014-03-05 Novartis AG Injectable vaccines against multiple meningococcal serogroups
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
JP2006525330A (ja) 2003-04-16 2006-11-09 ワイエス・ホールディングス・コーポレーション 髄膜炎菌性疾患の予防および処置のための新規免疫原性組成物
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
MXPA05014171A (es) 2003-06-23 2007-02-21 Sanofi Pasteur Inc Metodo de inmunizacion contra neisseria meningitidis serogrupos a y c.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CA2885040C (en) 2003-10-02 2018-10-30 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
US7608278B2 (en) 2003-12-30 2009-10-27 Wyeth Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
SI1740217T1 (sl) 2004-04-30 2011-10-28 Novartis Ag Konjugirano meningokokno cepljenje
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
ATE493437T1 (de) 2004-07-23 2011-01-15 Novartis Vaccines & Diagnostic Polypeptide für die oligomerisierung von antigenen
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
EP2682126B1 (en) 2005-01-27 2016-11-23 Children's Hospital & Research Center at Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
JP2008533016A (ja) 2005-03-07 2008-08-21 アイディー バイオメディカル コーポレイション オブ ケベック シー．オー．ビー． アズ グラクソスミスクライン バイオロジカルズ ノース アメリカ 薬学的リポソーム組成物
AU2006245440B2 (en) 2005-05-06 2012-04-19 Novartis Vaccines And Diagnostics Srl Immunogens for meningitidis-A vaccines
KR101408113B1 (ko) 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
EP1931380A2 (en) 2005-09-01 2008-06-18 Novartis Vaccines and Diagnostics GmbH & Co. KG Multiple vaccination including serogroup c meningococcus
ES2522521T3 (es) 2005-09-05 2014-11-14 Glaxosmithkline Biologicals Sa Ensayo bactericida del suero para antisueros específicos de N. meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
BRPI0620418A2 (pt) 2005-12-23 2011-11-08 Glaxosmithkline Biolog Sa método para imunizar um paciente humano contra uma doença, usos de pelo menos dois e de pelo menos sete, dez, onze, treze ou quatorze conjugados e das vacinas, e, kit
NZ572054A (en) 2006-03-22 2011-12-22 Novartis Ag Regimens for immunisation with meningococcal conjugates
US20070253985A1 (en) 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US20090123499A1 (en) 2006-06-12 2009-05-14 Nathalie Devos Vaccine
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
NZ573931A (en) 2006-06-29 2012-03-30 Craig J Venter Inst Inc Polypeptides from neisseria meningitidis
CA2657135C (en) 2006-07-27 2016-03-15 Wyeth High-cell density fed-batch fermentation process for producing recombinant protein
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
RU2009149359A (ru) 2007-06-04 2011-07-20 Новартис АГ (CH) Состав вакцин против менингита
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2185576A4 (en) 2007-08-02 2011-01-12 Childrens Hosp & Res Ct Oak FHBP- AND LPXL1-BASED VESICIUM VACCINES FOR BROADBAND PROTECTION AGAINST NEISSERIA MENINGITIDIS-RELATED DISEASES
ATE553774T1 (de) 2007-10-19 2012-05-15 Novartis Ag Meningokokkenimpfstoffformulierungen
BRPI0907843A2 (pt) 2008-02-21 2015-08-04 Novartis Ag Polipeptídeos de fhbp menigocócicos
AU2009221180B2 (en) 2008-03-05 2014-02-13 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
US20100035234A1 (en) 2008-05-19 2010-02-11 Novartis Ag Vaccine assays
RU2477145C2 (ru) 2008-05-30 2013-03-10 ДЗЕ Ю.Эс.Эй., ЭС РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТАРИ ОФ ДЗЕ АРМИ, ОН БЕХАФ ОФ УОЛТЕР РИД АРМИ Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения
EP2326726A4 (en) 2008-08-27 2011-09-28 Childrens Hosp & Res Ct Oak FACTOR-BASED H-FACTOR ASSAYS TO DETERMINE BACTERICIDE SERIAL ACTIVITY AGAINST NEISSERIA MENINGITIDIS
EP2331562A4 (en) 2008-09-03 2012-07-04 Childrens Hosp & Res Ct Oak PEPTIDES WITH AN EPITOPE OF A DOMAIN OF THE FACTOR H-BINDING PROTEIN AND METHOD OF USE
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
EP2362767B1 (en) 2008-10-29 2017-12-06 Ablynx N.V. Formulations of single domain antigen binding molecules
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
JP5410084B2 (ja) * 2008-12-15 2014-02-05 川上産業株式会社 梱包箱及び箱状芯材
US20100189737A1 (en) 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
NZ595291A (en) 2009-03-24 2013-08-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
RU2557315C2 (ru) 2009-03-24 2015-07-20 Новартис Аг Адъювантный менингококковый белок, связывающий фактор н
MX2011011512A (es) 2009-04-30 2012-02-13 Novartis Vaccines & Diagnostic Proteinas de union de factor h quimericas (fhbp) y metodos de uso.
US9365885B2 (en) 2009-06-16 2016-06-14 Puiying Annie Mak High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
JP3158225U (ja) * 2009-10-22 2010-03-25 王　文燦 折畳める物置袋
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CN102869377A (zh) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
EP4036104B1 (en) 2010-03-30 2024-02-21 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
PT2608805T (pt) 2010-08-23 2017-09-11 Wyeth Llc Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis
EP2612148B1 (en) 2010-09-04 2019-06-12 GlaxoSmithKline Biologicals SA Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
US20120070457A1 (en) 2010-09-10 2012-03-22 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
US9181308B2 (en) 2011-03-28 2015-11-10 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
JP5925342B2 (ja) 2012-03-09 2016-05-25 ファイザー・インク 髄膜炎菌（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
US9965924B2 (en) 2013-07-15 2018-05-08 Ahmnon D. Moskowitz Methods, systems, and apparatus for playing multi-zone 21
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
IL303108B2 (en) 2017-01-31 2024-07-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07508972A (ja) * 1989-03-09 1995-10-05 アメリカン・サイアナミド・カンパニー 分類できないヘモフイルス・インフルエンザエに対するワクチン
WO1996040718A1 (en) * 1995-06-07 1996-12-19 Connaught Laboratories, Inc. Expression of lipoproteins
WO1999040200A1 (en) * 1998-02-03 1999-08-12 Center For Disease Control And Prevention RECOMBINANT LIPIDATED PsaA PROTEIN, METHODS OF PREPARATION AND USE
WO1999057280A2 (en) * 1998-05-01 1999-11-11 Chiron Corporation Neisseria meningitidis antigens and compositions
WO2001037863A2 (en) * 1999-11-29 2001-05-31 Chiron Spa Compositions comprising neisseria meningitidis antigens from serogroups b and c as well as a further antigen
WO2001064920A2 (en) * 2000-02-28 2001-09-07 Chiron Spa Hybrid expression of neisserial proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6009003176, Ｉｎｆｅｃｔｉｏｎ ａｎｄ Ｉｍｍｕｎｉｔｙ, 1985, Ｖｏｌ． ４７， Ｎｏ． ２, ｐｐ．５２７−５３３ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010162038A (ja) * 2002-11-22 2010-07-29 Chiron Srl 髄膜炎菌タンパク質ｎｍｂ１８７０の複数の改変体
JP4767540B2 (ja) * 2002-11-22 2011-09-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 髄膜炎菌タンパク質ｎｍｂ１８７０の複数の改変体
JP2006525330A (ja) * 2003-04-16 2006-11-09 ワイエス・ホールディングス・コーポレーション 髄膜炎菌性疾患の予防および処置のための新規免疫原性組成物
JP2016222701A (ja) * 2006-04-26 2016-12-28 ワイス・エルエルシー 免疫原性組成物を安定化させ、沈殿を阻害する新規製剤
JP2013540705A (ja) * 2010-08-23 2013-11-07 ワイス・エルエルシー ナイセリア・メニンギティディス（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）ｒＬＰ２０８６抗原の安定な製剤
JP2013537884A (ja) * 2010-09-10 2013-10-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 髄膜炎菌に対するワクチン
JP2013540432A (ja) * 2010-09-10 2013-11-07 ワイス・エルエルシー 髄膜炎菌ｏｒｆ２０８６抗原の非脂質化変異体

Also Published As

Publication number Publication date
LUC00041I2 (cg-RX-API-DMAC10.html) 2017-12-20
DK2341062T3 (en) 2017-05-08
CN102755631B (zh) 2015-11-25
EP2371838A1 (en) 2011-10-05
EP2341063A3 (en) 2011-09-14
CN1578785B (zh) 2013-03-13
US8101194B2 (en) 2012-01-24
CA2463476C (en) 2017-09-12
AU2009213040C1 (en) 2012-10-11
PT2348036E (pt) 2016-03-09
JP5976880B2 (ja) 2016-08-24
EP2348034B1 (en) 2016-11-02
JP5404441B2 (ja) 2014-01-29
EP2348034A3 (en) 2011-09-21
JP2010162023A (ja) 2010-07-29
NL300899I2 (nl) 2018-04-06
FR15C0056I1 (cg-RX-API-DMAC10.html) 2015-09-11
US20190151431A1 (en) 2019-05-23
NL300896I1 (nl) 2017-10-20
DK2341063T3 (en) 2015-10-26
EP2348035A2 (en) 2011-07-27
MX339524B (es) 2016-05-30
FR17C1044I1 (cg-RX-API-DMAC10.html) 2017-12-22
ES2562811T3 (es) 2016-03-08
ES2603532T3 (es) 2017-02-28
AU2012202916A1 (en) 2012-06-07
JP2015214545A (ja) 2015-12-03
EP1442047A2 (en) 2004-08-04
EP2348035B1 (en) 2015-02-18
US20120201844A1 (en) 2012-08-09
LUC00042I1 (cg-RX-API-DMAC10.html) 2017-10-16
FR17C1043I2 (fr) 2018-12-07
NL300755I2 (nl) 2025-11-25
US20170173140A1 (en) 2017-06-22
ES2532639T3 (es) 2015-03-30
US20120301496A1 (en) 2012-11-29
MX349481B (es) 2017-07-31
EP1442047A4 (en) 2005-06-01
PT2332961T (pt) 2016-09-28
ES2568895T3 (es) 2016-05-05
ES2603531T3 (es) 2017-02-28
PT2371836T (pt) 2017-02-17
EP2348034A2 (en) 2011-07-27
EP3199539A1 (en) 2017-08-02
IL233545A (en) 2017-10-31
EP2351767A3 (en) 2011-09-14
KR20100121699A (ko) 2010-11-18
FR17C1042I2 (fr) 2018-12-07
EP2341063B1 (en) 2015-08-26
DK2343308T3 (en) 2015-03-30
AU2009213040B2 (en) 2012-03-01
US8563007B1 (en) 2013-10-22
CA2849427A1 (en) 2003-08-07
KR20110117726A (ko) 2011-10-27
US11116829B2 (en) 2021-09-14
CA2939781A1 (en) 2003-08-07
NL300899I1 (nl) 2017-10-20
AU2009213040A1 (en) 2009-10-08
EP2341062A2 (en) 2011-07-06
BRPI0212999B8 (pt) 2021-07-27
PT2341063E (pt) 2015-10-29
AU2018203627A1 (en) 2018-06-07
US9132182B2 (en) 2015-09-15
DK2332961T3 (en) 2016-10-03
CN102836426B (zh) 2016-09-28
CA2939781C (en) 2022-09-13
BRPI0212999B1 (pt) 2020-04-28
KR20100028657A (ko) 2010-03-12
IL233545A0 (en) 2014-08-31
WO2003063766A2 (en) 2003-08-07
CA2918207A1 (en) 2003-08-07
WO2003063766A3 (en) 2004-01-08
IL161052A0 (en) 2004-08-31
ES2549764T3 (es) 2015-11-02
IL245955A0 (en) 2016-07-31
EP2366707A1 (en) 2011-09-21
FR17C1043I1 (cg-RX-API-DMAC10.html) 2017-12-22
EP2332961A3 (en) 2011-07-27
EP2371837B1 (en) 2016-09-21
LU92786I2 (fr) 2015-11-02
ES2593360T3 (es) 2016-12-07
CN102836426A (zh) 2012-12-26
ES2615206T3 (es) 2017-06-05
EP2366707B1 (en) 2016-09-21
BR0212999A (pt) 2006-05-23
BE2017C057I2 (cg-RX-API-DMAC10.html) 2022-02-01
NL300897I1 (nl) 2017-10-20
US20130259889A1 (en) 2013-10-03
US20120308595A1 (en) 2012-12-06
DK2348036T3 (en) 2016-02-22
KR20040066793A (ko) 2004-07-27
JP2017025061A (ja) 2017-02-02
EP2341062A3 (en) 2011-09-14
KR101099916B1 (ko) 2011-12-28
MXPA04003356A (es) 2004-11-29
HK1178800A1 (zh) 2013-09-19
CA2894296C (en) 2018-05-01
CN105617372A (zh) 2016-06-01
EP2332961A2 (en) 2011-06-15
ES2609039T3 (es) 2017-04-18
CA2849427C (en) 2016-10-04
IL161052A (en) 2015-04-30
EP2371836B1 (en) 2016-12-14
PT2371838E (pt) 2016-03-23
PT2351767E (pt) 2015-10-30
PT2341062T (pt) 2017-06-02
US20110076299A1 (en) 2011-03-31
US9623101B2 (en) 2017-04-18
US9168293B2 (en) 2015-10-27
ES2549765T3 (es) 2015-11-02
HK1178429A1 (zh) 2013-09-13
EP2348036B1 (en) 2015-12-16
IL245955B (en) 2018-01-31
EP2351767B1 (en) 2015-08-26
CN102755631A (zh) 2012-10-31
US20150335724A1 (en) 2015-11-26
US20200138933A1 (en) 2020-05-07
EP2348036A2 (en) 2011-07-27
AU2012202916B2 (en) 2013-08-01
JP2014012002A (ja) 2014-01-23
CN1578785A (zh) 2005-02-09
PT2348035E (pt) 2015-03-25
IL245956A0 (en) 2016-07-31
JP5997400B2 (ja) 2016-09-28
JP5923070B2 (ja) 2016-05-24
EP2348036A3 (en) 2011-08-03
PT3199539T (pt) 2020-04-01
EP2371837A1 (en) 2011-10-05
DK2371838T3 (en) 2016-02-22
ES2625876T3 (es) 2017-07-20
EP2348035A3 (en) 2011-09-14
EP2343308B1 (en) 2015-02-18
LUC00040I2 (cg-RX-API-DMAC10.html) 2017-12-20
EP2351767A2 (en) 2011-08-03
JP2016165275A (ja) 2016-09-15
AU2012202916C1 (en) 2017-06-08
EP2341063A2 (en) 2011-07-06
ES2781213T3 (es) 2020-08-31
US20120034261A1 (en) 2012-02-09
CA2463476A1 (en) 2003-08-07
DK2348035T3 (en) 2015-04-20
EP2371836A1 (en) 2011-10-05
ES2532640T3 (es) 2015-03-30
US20120294880A1 (en) 2012-11-22
EP2343308A2 (en) 2011-07-13
LUC00040I1 (cg-RX-API-DMAC10.html) 2017-10-16
US10300122B2 (en) 2019-05-28
IL245956B (en) 2019-02-28
DK2371836T3 (en) 2017-02-20
ES2561430T3 (es) 2016-02-26
NL300896I2 (nl) 2018-04-06
PT2343308E (pt) 2015-03-25
CA2918207C (en) 2016-10-18
EP2341062B1 (en) 2017-03-29
NL300897I2 (nl) 2018-04-06
LUC00041I1 (cg-RX-API-DMAC10.html) 2017-10-16
DK3199539T3 (da) 2020-04-27
US8563006B2 (en) 2013-10-22
FR15C0056I2 (fr) 2016-06-03
BE2017C055I2 (cg-RX-API-DMAC10.html) 2022-02-01
EP3199539B1 (en) 2020-03-11
FR17C1042I1 (cg-RX-API-DMAC10.html) 2017-12-22
DK2351767T3 (en) 2015-10-26
US20150216960A1 (en) 2015-08-06
BE2017C056I2 (cg-RX-API-DMAC10.html) 2022-02-01
EP2343308A3 (en) 2011-07-27
CA2894296A1 (en) 2003-08-07
EP2332961B1 (en) 2016-07-27
KR101068318B1 (ko) 2011-09-28
KR101215664B1 (ko) 2012-12-26
US9107873B2 (en) 2015-08-18
US9757444B2 (en) 2017-09-12
EP1442047B1 (en) 2016-03-16
EP2371838B1 (en) 2015-12-16
LUC00042I2 (cg-RX-API-DMAC10.html) 2017-12-20
US20060257413A1 (en) 2006-11-16
FR17C1044I2 (fr) 2018-12-07

Similar Documents

Publication Publication Date Title
JP5997400B2 (ja) 髄膜炎性疾患の予防および治療のための新規免疫原性組成物
JP2006525330A (ja) 髄膜炎菌性疾患の予防および処置のための新規免疫原性組成物
JP2010512792A (ja) 髄膜炎菌性疾患の予防および処置のための新規な免疫原性組成物
HK1178800B (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
HK1178429B (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
AU2002365219A1 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090424

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090727

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100118

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100408

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100514

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20110517

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110518